Chemotherapy Dose Modifications

Introduction to Chemotherapy Dose Modifications

The National Comprehensive Cancer Network recommends calculating creatinine clearance or eGFR before each chemotherapy cycle, and monitoring BUN, serum creatinine, and electrolytes to assess renal function 1, 2
The National Comprehensive Cancer Network suggests considering 24-hour urine collection for accurate GFR in borderline cases 1, 2

For patients with GFR < 60 mL/min, the National Comprehensive Cancer Network recommends considering carboplatin substitution 1, 2
For patients with borderline renal function, the National Comprehensive Cancer Network suggests considering split-dose cisplatin administration (35 mg/m² on days 1 and 2 or days 1 and 8) 1, 2
The National Comprehensive Cancer Network recommends a required hydration protocol for cisplatin, including pre-hydration with 1-2 L isotonic saline and post-hydration with continued IV fluids for several hours after infusion 1, 2, 3, 4
Cisplatin administration is associated with hypomagnesemia, which may persist long-term, emphasizing the need for careful electrolyte management in patients receiving cisplatin therapy 5
Long-term nephrotoxicity is frequently asymptomatic but may be associated with up to a 30% reduction in glomerular filtration rate (GFR), highlighting the importance of monitoring renal function in patients treated with cisplatin 5
Even small reductions in GFR have an adverse impact on cardiovascular disease and all-cause mortality, underscoring the need for preventive measures in patients receiving cisplatin 5
Renal function typically decreases in a dose-dependent pattern after cisplatin therapy and then either remains stable or improves during the next 5–10 years, suggesting a potential for recovery with appropriate management 5

For bladder cancer patients with normal organ function, the National Comprehensive Cancer Network recommends standard regimens such as gemcitabine + cisplatin or DDMVAC with growth factor support 1, 2
For bladder cancer patients with renal impairment, the National Comprehensive Cancer Network suggests switching to gemcitabine + carboplatin for GFR < 60 mL/min 1, 2
The National Comprehensive Cancer Network notes that carboplatin should not be substituted for cisplatin in the perioperative setting 1, 2

The National Comprehensive Cancer Network recommends checking renal function before each cycle and monitoring electrolytes, particularly magnesium, calcium, and potassium 1, 2, 3, 4
For patients with hepatic impairment, the National Comprehensive Cancer Network suggests monitoring LFTs closely and avoiding concomitant acetaminophen (limit to <1300 mg/day) 6
For patients with grade 3-4 LFT abnormalities, the National Comprehensive Cancer Network recommends holding the drug until grade 1 or better, then resuming at 25-33% dose reduction (not < 300 mg) 6
Monitoring renal function before each cycle, including checking blood urea nitrogen (BUN), creatinine, serum uric acid, and creatinine clearance, is crucial for preventing nephrotoxicity in patients receiving cisplatin therapy, as recommended by the National Comprehensive Cancer Network 3, 4, 5
Elderly patients require closer monitoring due to higher susceptibility to nephrotoxicity, as recommended by the National Comprehensive Cancer Network 3, 4

Adequate hydration before, during, and after cisplatin administration is essential to prevent cisplatin-induced nephrotoxicity, with intravenous fluids required before and after each cycle of cisplatin, as recommended by the National Comprehensive Cancer Network 3, 4
A typical hydration regimen includes pre-hydration with isotonic saline (1-2 L) prior to cisplatin administration and post-hydration continuing IV fluids for several hours after cisplatin infusion, as suggested by the National Comprehensive Cancer Network 3, 4
Patients may require continued IV fluids (5-7 days) in an outpatient setting to prevent or treat dehydration, according to the National Comprehensive Cancer Network 3, 4
Dose reduction (75 mg/m² vs 100 mg/m²) may help decrease toxicity, as recommended by the National Comprehensive Cancer Network 3, 4
Adding 8-16 milliequivalents of magnesium to the hydration regimen may help prevent hypomagnesemia and have nephroprotective effects, as recommended by the National Comprehensive Cancer Network 4
Patients should be monitored for myelosuppression, dehydration, electrolyte loss, and other end-organ toxicities, and provided with supportive care as needed, according to the National Comprehensive Cancer Network 3

The National Comprehensive Cancer Network warns against misattributing LFT abnormalities to liver metastases, as most are mild to moderate and normalize within one year of stopping treatment 1, 2
The National Comprehensive Cancer Network notes that inadequate hydration with cisplatin can significantly increase nephrotoxicity risk, and that long-term nephrotoxicity may be asymptomatic but can reduce GFR by up to 30% 1, 2
The National Comprehensive Cancer Network cautions against inappropriate carboplatin substitution, as it should not be substituted for cisplatin in perioperative settings 1, 2
The National Comprehensive Cancer Network advises against overlooking drug interactions, as certain medications can inhibit or induce CYP450 3A4 and affect chemotherapy drug concentrations 6